Target intelligence / Profile preview

Cyclin-dependent kinase 5 (with p35 regulatory subunit) (CDK5–p35)

Target
CDK5–p35
Molecular classification
Enzyme (Serine/threonine kinase), Cyclin-dependent kinase complex, Protein complex regulator
01

Overview

The CDK5–p35 complex is a neuron-specific serine/threonine kinase complex in which the p35 regulatory subunit activates cyclin-dependent kinase 5 (CDK5). Unlike other cyclin-dependent kinases, CDK5 is not involved in cell cycle regulation but in neuronal migration, differentiation, axon guidance, and synaptic function. p35 is necessary for the activation of CDK5 in post-mitotic neurons, guiding its subcellular localization and enabling its function in the developing and mature brain. Disruption of the CDK5–p35 axis, such as the production of the aberrant activator p25 (truncated from p35), is implicated in neurodegenerative pathologies like Alzheimer's disease, due to the deregulation of kinase activity and subsequent hyperphosphorylation of neuronal substrates.

Other names
Cdk5-p35 complexCdk5/activator 1 complexCyclin-dependent kinase 5 with p35CDK5/CDK5R1 complex
02

Mechanism of action

Inhibition of CDK5 kinase activity (typically by blocking ATP-binding or by disrupting p35 binding). Modulation of p35 phosphorylation, processing, or destruction.

03

Biological functions

Neuronal development and migrationNeurite outgrowthNeurotransmitter releaseRegulation of cytoskeletal dynamics (actin reorganization)Cell differentiation (neuronal)
04

Disease associations

Neurodegenerative disease (notably Alzheimer’s disease)Cancer (implicated but less commonly a primary target)Neuropathic painOther CNS disorders
05

Safety considerations

Ubiquitous kinase targets raise concerns of off-target effectsCDK5 inhibition may interfere with normal brain development and neuronal function, which is especially critical in the developing or aging CNS
06

Interacting drugs

Roscovitine (Seliciclib): a CDK inhibitor

2 more in the full profile.

07

Biomarkers

p25 fragment (a cleavage product of p35 linked to disease progression, especially in Alzheimer’s)CDK5 activity levels in brain tissue

Beyond the preview

Go deeper on Cyclin-dependent kinase 5 (with p35 regulatory subunit) (CDK5–p35).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin-dependent kinase 5 (with p35 regulatory subunit) (CDK5–p35).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call